CinDome Pharma, a Cincinnati, OH-based company dedicated to advancing a safe, chronic therapy for gastroparesis, raised $40M in Series B extension funding.
The round, which brought the total amount to $59M, included participation from Perceptive Advisors and CinRx Pharma.
The company intends to use the funds for the ongoing enrollment and evaluation of deudomperidone in the Phase 2Ā envision3DĀ study in adults with diabetic gastroparesis and position itself for registrational trials.
CinDome is dedicated to advancing a safe, effective and tolerable treatment for people living with the devastating impact of chronic gastroparesis. āIts deudomperidone (CIN-102) is an engineered formulation of well-known D2/D3 antagonist, domperidone, which is the first-line treatment for gastroparesis worldwide but not approved in the U.S. ā
FinSMEs
16/05/2024